AEGiS-11IAC: Interaction of HIV and SIV envelope glycoproteins with lipids and glycolipids.

11th International AIDS Conference


Vancouver, British Columbia — July 7-12, 1996

Print this Article


Interaction of HIV and SIV envelope glycoproteins with lipids and glycolipids.

Int Conf AIDS 1996 Jul 7-12; 11:218 (abstract no. Tu.A.144)
Elmostafa B, Moulard M, Elmeskini R, Canarelli S, Montagnier L; Universite Paul Sabatier, Toulouse, France.

OBJECTIVE: To study the interaction between HIV-1, HIV-2 and SIV enveloppe glycoproteins and glycolipids.

METHODS: Two complementary approaches have been used to investigate the interaction between HIV-1, HIV-2 and SIV envelope glycoproteins and glycolipids (galactosylceramide, glucosylceramide, lactosylceramide) or ceramide. In the first approach, glycolipids were chromatographed on HPTLC or fixed on microtitration plates and then incubated with radiolabelled glycoproteins. The second approach used a plasma membrane model of monomolecular films composed of ceramide and different glycolipids.

RESULTS: The analysis of viral glycoproteins and glycolipids according the first approach, showed an interaction between HIV or SIV envelope glycoproteins and galactosylceramide, as described previously by others, but there was also an interaction with glucosylceramide and lactosylceramide. More surprisingly, this approach enabled us to demonstrate an interaction between glycoproteins and ceramide. In order to confirm these results, a second assay involving a plasma model composed of ceramide and different glycoproteins was used to study this interaction. Here again, it was found that in addition to the interaction of recombinant HIV-1 glycoproteins gp160/gp120 with the glycolipids (galactosylceramide, glucosylceramide and lactosylceramide), these glycoproteins could also interact with ceramide.

CONCLUSIONS: In summary, our work, using different techniques, has shown that the binding of HIV and SIV glycoproteins to GalCer, GlucCer, LacCer and ceramide is dose-dependent, can be saturated and can be selectively inhibited by envelope glycoprotein antibodies. These findings enable us to propose hypotheses to understand the infection of CD4-negative and GalCer-negative cells, as has recently be described for primary human brain endothelial cells.

Keywords: AEGIS, SIV, HIV, Glycolipids, HIV-2, Glycoproteins, HIV-1, HIV Envelope Protein gp120, Galactosylceramides, Antigens, CD4, Receptors, HIV, HIV Envelope Protein gp41, Glucosylceramides, HIV Envelope Protein gp160, HIV Core Protein p24, Human, ICA11KWDaegis,siv,hiv,glycolipids,hiv-2,glycoproteins,hiv-1,hivenvelopeproteingp120,galactosylceramides,antigens,cd4,receptors,hiv,hivenvelopeproteingp41,glucosylceramides,hivenvelopeproteingp160,hivcoreproteinp24,human,ica11

960707
TuA144

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.